Raymond James Financial Services Advisors’s OrthoPediatrics KIDS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-15,157
Closed -$485K 3365
2023
Q3
$485K Hold
15,157
﹤0.01% 2351
2023
Q2
$665K Hold
15,157
﹤0.01% 2170
2023
Q1
$671K Hold
15,157
﹤0.01% 2149
2022
Q4
$602K Hold
15,157
﹤0.01% 2160
2022
Q3
$699K Hold
15,157
﹤0.01% 2054
2022
Q2
$654K Sell
15,157
-47
-0.3% -$2.15K ﹤0.01% 2109
2022
Q1
$821K Hold
15,204
﹤0.01% 2077
2021
Q4
$910K Buy
15,204
+47
+0.3% +$2.93K ﹤0.01% 2032
2021
Q3
$993K Sell
15,157
-21
-0.1% -$1.36K ﹤0.01% 1965
2021
Q2
$959K Buy
15,178
+21
+0.1% +$1.21K ﹤0.01% 1978
2021
Q1
$739K Sell
15,157
-18
-0.1% -$864 ﹤0.01% 2049
2020
Q4
$626K Hold
15,175
﹤0.01% 2003
2020
Q3
$697K Buy
15,175
+18
+0.1% +$835 ﹤0.01% 1774
2020
Q2
$663K Hold
15,157
﹤0.01% 1742
2020
Q1
$601K Hold
15,157
﹤0.01% 1441
2019
Q4
$712K Hold
15,157
﹤0.01% 1746
2019
Q3
$534K Hold
15,157
﹤0.01% 1861
2019
Q2
$591K Buy
+15,157
New +$611K ﹤0.01% 1815

Other funds holding KIDS

Raymond James Financial Services Advisors's KIDS Position: Q4 2023 in Review

Raymond James Financial Services Advisors sold out of OrthoPediatrics (KIDS) in Q4 2023, closing a stake of 15,157 shares — an estimated $485K sold.

Raymond James Financial Services Advisors first reported a position in KIDS in Q2 2019 and held it in 18 quarters. The position peaked at $993K in Q3 2021. 129 funds tracked by Wall St. Rank hold KIDS as of Q4 2023.

  • Raymond James Financial Services Advisors reported no remaining OrthoPediatrics position as of Q4 2023 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 15,157 OrthoPediatrics shares in Q4 2023, an estimated $485K.
  • Raymond James Financial Services Advisors first reported a position in OrthoPediatrics in Q2 2019 and held it in 18 quarters.
  • Raymond James Financial Services Advisors's OrthoPediatrics position peaked at $993K in Q3 2021.
  • 129 funds tracked by Wall St. Rank held OrthoPediatrics as of Q4 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.